Neurocrine Biosciences Stock Price (NASDAQ:NBIX)

Add to My Stocks
$47.79 $0.06 (0.13%) NBIX stock closing price Jul 20, 2017 (Closing)
Prev Close* : $47.73
Market Cap:
$4.17B
Day Low: $47.42
52 Week Low: $37.35
Open: $47.87
Volume: 506641
Day High: $48.2
52 Week High: $55.38
Dividend:
N/A

Neurocrine Biosciences Stock Articles & Video

more news on NBIX stock

Neurocrine Biosciences News - From Partners

Company News for April 13, 2017   by Zacks on Apr 13, 2017

NBIX Stockcharts

View NBIX PE ratio, PS ratio stocks charts and compare with peers.
NBIX Chart
Note: Compare Neurocrine Biosciences stock price history with the index and industry peers.

NBIX Industry Peers

Company Price Change (%)
Anacor Pharma (ANAC)99.20 (0%)
Catalent (CTLT)35.850.22 (0.61%)
Abbvie (ABBV)74.011.24 (1.7%)
Repros Therapeutics (RPRX)0.40.02 (5.26%)
Auspex Pharma (ASPX)100.960 (0%)
Sage Therapeutics (SAGE)81.410.44 (0.54%)
Pfizer (PFE)33.540.08 (0.24%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
Tetraphase Pharmaceuticals (TTPH)7.870.46 (6.21%)
Esperion Therapeutics (ESPR)48.82.6 (5.63%)
PTC Therapeutics (PTCT)20.340.91 (4.68%)
GlycoMimetics (GLYC)11.830.52 (4.6%)
MediWound (MDWD)7.250.3 (4.32%)
Catalyst Pharma (CPRX)3.050.12 (4.1%)
Tesaro Inc (TSRO)129.025 (4.03%)
Top gainers from Medical-Drugs industry
* As of Jul 20, 2017
CompanyPriceChange (%)
Adamis Pharma (ADMP)4.650.45 (8.82%)
Ironwood Pharma (IRWD)171.55 (8.36%)
Ignyta (RXDX)8.80.4 (4.35%)
Xencor (XNCR)230.62 (2.62%)
Achaogen (AKAO)22.310.47 (2.06%)
Enanta Pharma (ENTA)36.420.6 (1.62%)
Shire (SHPG)160.222.57 (1.58%)
Top losers from Medical-Drugs industry
* As of Jul 20, 2017

Neurocrine Biosciences, Inc. Stock News - Partner Headlines

Neurocrine Biosciences Financial Statements

income statement20162015201420132012
Net Sales Or Revenues15M19.76M-2.91M53.14M
Net Income-141.09M-88.92M-60.54M-46.09M5.02M
Total Operating Expense162.37M113.97M64.4M52.58M51.68M
view Neurocrine Biosciences, Inc. income statement
balance sheet20162015201420132012
Total Assets365.08M474.78M243.03M154.67M195.97M
Total Liabilities50.2M50.33M34.33M34.26M41.6M
Shareholders Equity314.87M424.45M208.69M120.41M154.37M
view Neurocrine Biosciences, Inc. balance sheet
cash flow statement20162015201420132012
Net Increase (Decrease) In Assets Liabilities5.78M8.7M1.6M12.23M-13.36M
Net Cash From (Used By) Operating Activities-106.18M-37.99M-47.14M-29.6M-35.29M
Increase (Decrease) In Prop Plant And Equipment-4.09M-1.92M-1.56M-0.5M-0.93M
view Neurocrine Biosciences, Inc. cashflow statement

Neurocrine Biosciences Stock Message Board

Neurocrine Biosciences stock lost 0.76 %, and the last close price as of 19 Jul, 2017 is 47.73 for NBIX stock. Looking at Neurocrine Biosciences market capitalization, which currently stands at 4.17B, we can say that NBIX stock is a Mid cap stock. Investors can use valuation multiples like the P/E ratio, price to sales ratio etc. for performing Neurocrine Biosciences stock analysis.

Demand for a stock decides its stock market price. For example, if more investors want to buy NBIX stock than sell it, then Neurocrine Biosciences stock price goes up. Conversely, if more investors wanted to sell NBIX stock than buy it, there would be greater supply than demand, and the stock price would fall. 866333 NBIX shares were traded yesterday, and Neurocrine Biosciences stock chart shows that the NBIX stock quote hit a day high of 48.58 and day low of 47.34. Dividends are usually paid by large stable companies, and typically not by those which are in their rapid growth stages. A company's continuing success is indicated by a steadily increasing dividend payout. One can observe stock price trends and check for volatility by checking Neurocrine Biosciences stock price history.